Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2011 1
2012 4
2013 3
2014 2
2015 3
2016 5
2017 8
2018 5
2019 8
2020 7
2021 10
2022 8
2023 15
2024 3

Text availability

Article attribute

Article type

Publication date

Search Results

70 results

Results by year

Filters applied: . Clear all
Page 1
Two Phase 3, Randomized, Controlled Trials of Ruxolitinib Cream for Vitiligo.
Rosmarin D, Passeron T, Pandya AG, Grimes P, Harris JE, Desai SR, Lebwohl M, Ruer-Mulard M, Seneschal J, Wolkerstorfer A, Kornacki D, Sun K, Butler K, Ezzedine K; TRuE-V Study Group. Rosmarin D, et al. N Engl J Med. 2022 Oct 20;387(16):1445-1455. doi: 10.1056/NEJMoa2118828. N Engl J Med. 2022. PMID: 36260792
BACKGROUND: Vitiligo is a chronic autoimmune disease that causes skin depigmentation. A cream formulation of ruxolitinib (an inhibitor of Janus kinase 1 and 2) resulted in repigmentation in a phase 2 trial involving adults with vitiligo. METHODS: We conducted two ph …
BACKGROUND: Vitiligo is a chronic autoimmune disease that causes skin depigmentation. A cream formulation of ruxolitinib (an inhibito …
Vitiligo: Current Therapies and Future Treatments.
Seneschal J, Boniface K. Seneschal J, et al. Dermatol Pract Concept. 2023 Dec 1;13(4S2):e2023313S. doi: 10.5826/dpc.1304S2a313S. Dermatol Pract Concept. 2023. PMID: 38241396 Free PMC article. Review.
The current management of vitiligo remains challenging; however, different strategies can be proposed to patients with a good efficacy in many cases. ...For patients with a stable disease, the treatment strategy is now well-stratified and is based on a combination of photo …
The current management of vitiligo remains challenging; however, different strategies can be proposed to patients with a good efficac …
Editorial: Immunology of Vitiligo.
Seneschal J, Harris JE, Le Poole IC, Passeron T, Speeckaert R, Boniface K. Seneschal J, et al. Front Immunol. 2021 Jun 24;12:711080. doi: 10.3389/fimmu.2021.711080. eCollection 2021. Front Immunol. 2021. PMID: 34249018 Free PMC article. No abstract available.
An update on Vitiligo pathogenesis.
Seneschal J, Boniface K, D'Arino A, Picardo M. Seneschal J, et al. Pigment Cell Melanoma Res. 2021 Mar;34(2):236-243. doi: 10.1111/pcmr.12949. Epub 2020 Dec 15. Pigment Cell Melanoma Res. 2021. PMID: 33278065 Review.
Vitiligo, the most common depigmenting disorder of the skin, is undergoing a period of intense advances in both disease understanding and therapeutic possibilities leading the way to the beginning of a new era for the disorder. ...The complex interplay between non-immunolo …
Vitiligo, the most common depigmenting disorder of the skin, is undergoing a period of intense advances in both disease understanding …
Worldwide expert recommendations for the diagnosis and management of vitiligo: Position statement from the international Vitiligo Task Force-Part 2: Specific treatment recommendations.
Seneschal J, Speeckaert R, Taïeb A, Wolkerstorfer A, Passeron T, Pandya AG, Lim HW, Ezzedine K, Zhou Y, Xiang F, Thng S, Tanemura A, Suzuki T, Rosmarin D, Rodrigues M, Raboobee N, Pliszewski G, Parsad D, Oiso N, Monteiro P, Meurant JM, Maquignon N, Lui H, Le Poole C, Leone G, Lee AY, Lan E, Katayama I, Huggins R, Oh SH, Harris JE, Hamzavi IH, Gupta S, Grimes P, Goh BK, Ghia D, Esmat S, Eleftheriadou V, Böhm M, Benzekri L, Bekkenk M, Bae JM, Alomar A, Abdallah M, Picardo M, van Geel N. Seneschal J, et al. J Eur Acad Dermatol Venereol. 2023 Nov;37(11):2185-2195. doi: 10.1111/jdv.19450. Epub 2023 Sep 15. J Eur Acad Dermatol Venereol. 2023. PMID: 37715487
BACKGROUND: The treatment of vitiligo can be challenging. Up-to-date agreed consensus recommendations on the use of topical and systemic therapies to facilitate the clinical management of vitiligo are currently lacking. ...CONCLUSIONS: This international consensus s …
BACKGROUND: The treatment of vitiligo can be challenging. Up-to-date agreed consensus recommendations on the use of topical and syste …
Worldwide expert recommendations for the diagnosis and management of vitiligo: Position statement from the International Vitiligo Task Force Part 1: towards a new management algorithm.
van Geel N, Speeckaert R, Taïeb A, Ezzedine K, Lim HW, Pandya AG, Passeron T, Wolkerstorfer A, Abdallah M, Alomar A, Bae JM, Bekkenk M, Benzekri L, Böhm M, Eleftheriadou V, Esmat S, Ghia D, Goh BK, Grimes P, Gupta S, Hamzavi IH, Harris JE, Oh SH, Huggins R, Katayama I, Lan E, Lee AY, Leone G, Le Poole C, Lui H, Maquignon N, Meurant JM, Monteiro P, Oiso N, Parsad D, Pliszewski G, Raboobee N, Rodrigues M, Rosmarin D, Suzuki T, Tanemura A, Thng S, Xiang F, Zhou Y, Picardo M, Seneschal J. van Geel N, et al. J Eur Acad Dermatol Venereol. 2023 Nov;37(11):2173-2184. doi: 10.1111/jdv.19451. Epub 2023 Sep 25. J Eur Acad Dermatol Venereol. 2023. PMID: 37746876
BACKGROUND: The treatment of vitiligo can be challenging and depends on several factors such as the subtype, disease activity, vitiligo extent, and treatment goals. Vitiligo usually requires a long-term approach. To improve the management of vitiligo w …
BACKGROUND: The treatment of vitiligo can be challenging and depends on several factors such as the subtype, disease activity, vit …
Special Considerations in Children with Vitiligo.
Taïeb A, Seneschal J, Mazereeuw-Hautier J. Taïeb A, et al. Dermatol Clin. 2017 Apr;35(2):229-233. doi: 10.1016/j.det.2016.11.011. Dermatol Clin. 2017. PMID: 28317531 Review.
Childhood vitiligo differs from adult-onset vitiligo for several features including increased incidence of the segmental variant, higher prevalence of halo nevi, and more common family history for autoimmune diseases and atopic diathesis. The major differential diag …
Childhood vitiligo differs from adult-onset vitiligo for several features including increased incidence of the segmental varia …
Vitiligo: Focus on Clinical Aspects, Immunopathogenesis, and Therapy.
Boniface K, Seneschal J, Picardo M, Taïeb A. Boniface K, et al. Clin Rev Allergy Immunol. 2018 Feb;54(1):52-67. doi: 10.1007/s12016-017-8622-7. Clin Rev Allergy Immunol. 2018. PMID: 28685247 Review.
The nomenclature has been revised after an extensive international work within the vitiligo global issues consensus conference, and vitiligo (formerly non-segmental vitiligo) is now a consensus umbrella term for all forms of generalized vitiligo. Two o …
The nomenclature has been revised after an extensive international work within the vitiligo global issues consensus conference, and …
Vitiligo, From Physiopathology to Emerging Treatments: A Review.
Migayron L, Boniface K, Seneschal J. Migayron L, et al. Dermatol Ther (Heidelb). 2020 Dec;10(6):1185-1198. doi: 10.1007/s13555-020-00447-y. Epub 2020 Sep 19. Dermatol Ther (Heidelb). 2020. PMID: 32949337 Free PMC article. Review.
Vitiligo is a chronic inflammatory skin disease leading to the loss of epidermal melanocytes. ...In this review, based on the physiopathology of the disease, we summarize emerging targets that could be developed for the treatment of vitiligo and discuss recent and o …
Vitiligo is a chronic inflammatory skin disease leading to the loss of epidermal melanocytes. ...In this review, based on the physiop …
Clinician-reported outcome measures for the assessment of vitiligo: A scoping review.
van Geel N, Duponselle J, Delbaere L, Herbelet S, Eleftheriadou V, Ezzedine K, Forman M, Garg A, Hamzavi IH, Seneschal J, Spuls P, Terwee CB, Wolkerstorfer A, Speeckaert R, Pandya AG. van Geel N, et al. J Eur Acad Dermatol Venereol. 2023 Nov;37(11):2231-2242. doi: 10.1111/jdv.19448. Epub 2023 Sep 11. J Eur Acad Dermatol Venereol. 2023. PMID: 37602494 Review.
One global assessment score for extent has been validated. Vitiligo disease activity scores included a static measure of clinical activity signs (Vitiligo Signs of Activity Score [VSAS]) and two measures assessing dynamic evolution (Vitiligo Disease Activity …
One global assessment score for extent has been validated. Vitiligo disease activity scores included a static measure of clinical act …
70 results